Ixabepilone
- Generic Name
- Ixabepilone
- Brand Names
- Ixempra
- Drug Type
- Small Molecule
- Chemical Formula
- C27H42N2O5S
- CAS Number
- 219989-84-1
- Unique Ingredient Identifier
- K27005NP0A
- Background
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue ...
- Indication
用于在其他化学治疗均失效后作为治疗晚期乳腺癌的药物。
- Associated Conditions
- Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer
- Associated Therapies
- -
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 31
- Registration Number
- NCT01012362
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 1
- Registration Number
- NCT00998738
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy
- Conditions
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Registration Number
- NCT00998101
Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 58
- Registration Number
- NCT00983801
- Locations
- 🇨🇳
Local Institution, Taoyuan Hsien, Taiwan
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
- Conditions
- Endometrial Clear Cell AdenocarcinomaRecurrent Uterine Corpus CancerStage IIIA Uterine Corpus Cancer AJCC v7Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaStage IVA Uterine Corpus Cancer AJCC v7Stage IIIB Uterine Corpus Cancer AJCC v7Stage IIIC Uterine Corpus Cancer AJCC v7Endometrial Serous AdenocarcinomaStage IVB Uterine Corpus Cancer AJCC v7
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 349
- Registration Number
- NCT00977574
- Locations
- 🇺🇸
Henry Ford Health Warren Hospital, Warren, Michigan, United States
🇺🇸Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00923130
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸University of South Carolina, Charleston, South Carolina, United States
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- Accelerated Community Oncology Research Network
- Target Recruit Count
- 56
- Registration Number
- NCT00924352
- Locations
- 🇺🇸
Oncology Hematology Specialists, P.A., Denville, New Jersey, United States
🇺🇸Hematology Oncology PC, Stamford, Connecticut, United States
🇺🇸Northwest Georgia Oncology Centers, Marietta, Georgia, United States
Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Jaime Merchan
- Target Recruit Count
- 36
- Registration Number
- NCT00884676
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-04-17
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 551
- Registration Number
- NCT00883116
- Locations
- 🇺🇸
Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States
🇺🇸University Of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT00879086
- Locations
- 🇺🇸
Northwest Cancer Center, Corpus Christi, Texas, United States
🇺🇸Texas Oncology-Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Northern Utah Associates, Ogden, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.